The Dry Eye Zone

Rebecca's Blog

-

Drug News: LX214 update

Lux Biosciences announced on July 31 at ARVO their preclinical results from LX214, a calcineurin inhibitor Lux is "developing as a potential treatment for such conditions as dry eye syndrome, blepharitis, and atopic keratoconjunctivitis."

Click here for full press release

Results announced:
- Concentrations of LX214 (and/or residue) establish therapeutic levels in tear fluid and most ocular tissues, including conjunctiva, cornea, eyelids, sclera and lacrimal gland after single or multiple topical applications of the experimental drug. Blood levels of LX214 remained at or near base line, and there was minimal distribution of LX214 to the opposite, non-treated eye.

- Tissue concentrations of LX214 in the target tissues for ocular immune-mediated diseases were significantly higher than the tissue concentrations of cyclosporine A achieved by twice daily topical application of Restasis® (cyclosporine 0.05%). These results are particularly important given that voclosporin has been shown to be four-fold more potent than cyclosporine A.

- No evidence of clinical irritation was observed in any of the animals treated with LX214.

- No evidence of melanin binding by LX214 was observed.

“These data strongly support the further development of LX214 as a topical product for serious ocular inflammatory conditions as well as for dry eye syndrome,” said Ulrich Grau, Ph.D., President and Chief Executive Officer of Lux Biosciences. “We believe that the product has best-in-class potential based on the preclinical findings.”


Speaking of Lux, check their website for more information on LX214 and LX212. LX212 seems kind of vaguely reminiscent of Lacriserts.
Rebecca1 Comment